Based on the Acotec Scientific Holdings Ltd stock forecast from 0 analysts, the average analyst target price for Acotec Scientific Holdings Ltd is not available over the next 12 months. Acotec Scientific Holdings Ltd’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Acotec Scientific Holdings Ltd is Bearish, which is based on 2 positive signals and 7 negative signals. At the last closing, Acotec Scientific Holdings Ltd’s stock price was HKD 6.64. Acotec Scientific Holdings Ltd’s stock price has changed by +2.79% over the past week, +10.67% over the past month and -19.71% over the last year.
No recent analyst target price found for Acotec Scientific Holdings Ltd
No recent average analyst rating found for Acotec Scientific Holdings Ltd
Company Overview Acotec Scientific Holdings Ltd
Acotec Scientific Holdings Limited operates as an interventional medical device company that offers vascular interventional treatment products in Mainland China, Europe, and internationally. The company's products include AcoArt Orchid & Dhalia, a paclitaxel DCB used to prevent stenosis or occlusion in superficial femoral artery (SFA) and popliteal artery (PPA) for the treatment of lower extremity artery disease (LEAD) with a vascular interventional approach; and AcoArt Tulip & Litos, a paclitaxel coated DCB used to prevent stenosis or occlusion in below-theknee (BTK) arteries for the treatment of chronic limb-threatening ischemia with a vascular interventional approach. It also offers devices targeting vascular surgery, including AcoArt Iris & Jasmin; AcoArt Lily & Rosmarin; Peripheral Aspiration System (AcoStream); Radiofrequency Ablation System (AcoArt Cedar); Peripheral Support Catheter (Vericor); The PTA Balloon (P-Conic); and 2nd Gen Peripheral Aspiration System (2nd Generation AcoStream). In addition, its devices targeting cardiology include Semi-compliant PTCA Balloon (YAN), Coronary CTO Recanalization Balloon (RT-Zero), and Coronary CTO Antegrade Micro-Catheter (Vericor-14); devices targeting nephrology include Paclitaxel Coated High-Pressure Balloon (ACOART AVENS) and AV Scoring Balloon (Peridge); devices targeting neurology comprise Intracranial PTA Balloon (NEO-Skater); and devices targeting andrology include AcoArt Orchid & Dhalia and AcoArt Tulip & Litos. Further, the company trades procedural medical devices. The company was founded in 2011 and is headquartered in Beijing, China. Acotec Scientific Holdings Limited operates as a subsidiary of Boston Scientific Group plc. Read Less
Acotec Scientific Holdings Limited operates as an interventional medical device company that offers vascular interventional treatment products in Mainland China, Europe, and internationally. The company's products include AcoArt Orchid & Dhalia, a paclitaxel DCB used to prevent s...Read More
Frequently Asked Questions About Acotec Scientific Holdings Ltd (6669:HK) Stock
Stock Target Advisor's fundamental analysis for Acotec Scientific Holdings Ltd's stock is Bearish.
Unfortunately we do not have enough data on 6669:HK's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 6669:HK's stock to indicate what its average analyst target is.
6669:HK stock's Price/Earning ratio is 59.17.
Our analysis grades 6669:HK stock's Price / Earning ratio at F. This means that 6669:HK stock's Price/Earning ratio is above 77% of the stocks in the Medical Devices sector in the HK exchange.
Based on this 6669:HK may be a overvalued for its sector.
The last closing price of 6669:HK's stock was HKD 6.64.
The most recent market capitalization for 6669:HK is HKD 2.23B.
Unfortunately we do not have enough analyst data on 6669:HK's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Acotec Scientific Holdings Ltd's stock.
As per our most recent records Acotec Scientific Holdings Ltd has 615 Employees.
Acotec Scientific Holdings Ltd's registered address is Building No. 1, Beijing, China.
You can get more information about it from Acotec Scientific Holdings Ltd's website at https://www.acotec.cn.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Acotec Scientific Holdings Ltd (6669:HK) Stock
Stock Target Advisor's fundamental analysis for Acotec Scientific Holdings Ltd's stock is Bearish.
Unfortunately we do not have enough data on 6669:HK's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 6669:HK's stock to indicate what its average analyst target is.
6669:HK stock's Price/Earning ratio is 59.17.
Our analysis grades 6669:HK stock's Price / Earning ratio at F. This means that 6669:HK stock's Price/Earning ratio is above 77% of the stocks in the Medical Devices sector in the HK exchange.
Based on this 6669:HK may be a overvalued for its sector.
The last closing price of 6669:HK's stock was HKD 6.64.
The most recent market capitalization for 6669:HK is HKD 2.23B.
Unfortunately we do not have enough analyst data on 6669:HK's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Acotec Scientific Holdings Ltd's stock.
As per our most recent records Acotec Scientific Holdings Ltd has 615 Employees.
Acotec Scientific Holdings Ltd's registered address is Building No. 1, Beijing, China.
You can get more information about it from Acotec Scientific Holdings Ltd's website at https://www.acotec.cn.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 6669:HK !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
